No. HT942526BMFRPIIRA · Defense Health Agency Contracting Activity - DHACA
DoW Bone Marrow Failure, Investigator-Initiated Research Award
- Award range
- Not specified
- Expected awards
- ~1
- Application deadline
- Nov 4, 2026
- Posted
- Jun 17, 2026
- Last verified
- 3 days ago
At a glance
AI summaryThis program funds investigator-initiated research on inherited or acquired bone marrow failure diseases, including translational, clinical research, and IND-enabling studies, but it does not allow clinical trials. Applicants must include preliminary and/or published data relevant to bone marrow failure. Eligible applicants include U.S. Department of War organizations and foreign or domestic, for-profit or nonprofit organizations, and awards go to eligible organizations rather than individuals. The program expects to fund about one award, with total costs capped at $1.25 million and a maximum project period of 3 years. Cost sharing is not required, and the research must focus on bone marrow failure; primary focus on leukemia, myeloproliferative neoplasms, or other malignancies is not eligible.
AI-generated summary — verify against the announcement
What it funds
Official description from grants.gov
Summary: Supports studies that further develop mature ideas, expand upon key discoveries, and have the potential to make significant advances in bone marrow (BMF) failure research and/or patient care. Investigator-Initiated Research Award (IIRA) applications may involve translational and clinical research including studies in preclinical models, research with human data and/or anatomical substances, and research with human subjects, as well as correlative studies associated with a clinical trial(s); however, this award mechanism does not support clinical trials. IIRA applications may also support Investigational New Drug (IND)-enabling efforts such as lead compound characterization, and assessments of formulation and stability, absorption, distribution, metabolism and excretion, dose/response and toxicology. Distinctive Features: This funding mechanism allows for a partnering Principal Investigator (PI). Only the initiating PI will submit a pre-application, but both PIs will need to submit full applications. The partnering PI application is an abbreviated package specific to their distinct portion of the research project. Be advised, all associated applications for a research project may be withdrawn if the initiating or partnering application is rejected or administratively withdrawn. This award mechanism requires preliminary data relevant to the proposed project. Applications can support clinical research studies; however, this mechanism does not allow clinical trials.
Who can apply
- Unrestricted
Program history
USASpending.govAssistance listing 12.420 · Military Medical Research and Development
Real awards this federal program has made — the whole assistance listing (12.420), not just this notice.
| Fiscal year | Awards | Median award | Middle half |
|---|---|---|---|
| FY 2026 (so far) | 374 | $934,195 | $559,998 – $1,477,811 |
| FY 2025 | 967 | $796,174 | $416,995 – $1,480,602 |
| FY 2024 | 1,097 | — | — |
| FY 2023 | 1,115 | — | — |
| FY 2022 | 1,186 | — | — |
| FY 2021 | 1,023 | — | — |
Dollar figures are based on the 1,000 most recent awards we store, not all 5,762 — award counts are complete.
- THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER $19,100,256 · FY 2025
- H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE HOSPITAL, INC. $18,696,738 · FY 2025
- UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION, THE $10,606,583 · FY 2025
- SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH $10,500,000 · FY 2026
- UNIVERSITY OF VERMONT & STATE AGRICULTURAL COLLEGE $8,491,997 · FY 2025
Source: USASpending.gov · refreshed Aug 25, 2026